FindTrial
Sign In

PF-02341066

DRUG9 trials

Sponsors

Pfizer, University of Oxford

Conditions

Advanced Malignancies Except LeukemiaCarcinoma, Non-Small-Cell LungColorectal CancerHealthyHealthy VolunteerNon Small Cell Lung CancerNon-Small Cell Lung CancerNon-Small Cell Lung Cancer ALK-positive

Phase 1

A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer
CompletedNCT00585195
PfizerAdvanced Malignancies Except Leukemia, Non-Small Cell Lung Cancer ALK-positive, Non-Small Cell Lung Cancer c-Met Dependent +2
Start: 2006-04-19End: 2022-01-19Updated: 2023-02-08
Relative Drug Exposures Of Two Formulations of PF-02341066
CompletedNCT00939731
PfizerHealthy
Start: 2009-07-31End: 2009-08-31Updated: 2011-10-24
Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer
CompletedNCT00965731
PfizerNon-Small Cell Lung Cancer
Start: 2010-01-31End: 2014-01-31Updated: 2015-10-28
Radiolabeled [14C]PF-02341066 Study To Investigate The Absorption, Metabolism And Excretion In Healthy Male Volunteers
CompletedNCT01082380
PfizerHealthy Volunteer
Start: 2010-03-31End: 2010-04-30Updated: 2012-02-29
A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer
CompletedNCT01121575
PfizerNon Small Cell Lung Cancer
Start: 2010-08-31End: 2014-02-28Updated: 2015-10-28
A Study In Japanese Healthy Male Volunteers To Investigate The Safety, Tolerability And Pharmacokinetics Of PF-02341066
CompletedNCT01250730
PfizerHealthy
Start: 2010-12-31End: 2011-01-31Updated: 2011-11-29
MEK and MET Inhibition in Colorectal Cancer
CompletedNCT02510001
University of OxfordColorectal Cancer, Solid Tumor
Start: 2014-11-30End: 2018-12-03Updated: 2021-07-13

Phase 2

An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
CompletedNCT00932451
PfizerCarcinoma, Non-Small-Cell Lung
Start: 2010-01-31End: 2015-12-31Updated: 2017-01-13

Phase 3

An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
CompletedNCT00932893
PfizerCarcinoma, Non-Small-Cell Lung
Start: 2009-09-30End: 2016-01-31Updated: 2017-01-02

Related Papers

Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With <i>ROS1</i>-Positive Advanced NSCLC.
2022-09-0910 citations
Matching-Adjusted Indirect Comparison (MAIC) of Tepotinib with Other MET Inhibitors for the Treatment of Advanced NSCLC with MET Exon 14 Skipping Mutations.
2022-05-118 citations
Association of anticoagulant use with clinical outcomes from crizotinib in <i>ALK</i><scp><i>‐</i></scp> and <i>ROS1</i>‐rearranged advanced non‐small cell lung cancers: A retrospective analysis of <scp>PROFILE</scp> 1001
Cancer Medicine2022-05-057 citations
Crizotinib in Patients With MET-Amplified NSCLC.
2021-03-04124 citations
Ophthalmological assessment of crizotinib in advanced non-small-cell lung cancer.
2020-04-286 citations
Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study
Trials2020-03-307 citations
Dose-Escalation Trial of the ALK, MET &amp; ROS1 Inhibitor, Crizotinib, in Patients with Advanced Cancer
Future Oncology2019-11-2814 citations
Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.
2019-07-01381 citations
Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): Overall survival (OS) and updated safety from PROFILE 1001
Annals of Oncology2019-04-016 citations
Renal Effects of Crizotinib in Patients With ALK-Positive Advanced NSCLC.
2019-02-2612 citations
Comparison of Cardiovascular Effects of Crizotinib and Chemotherapy in ALK-Positive Advanced Non-Small-Cell Lung Cancer
Future Oncology2019-01-174 citations
Long-term safety of crizotinib in previously treated patients (pts) with ALK-positive advanced/metastatic non-small cell lung cancer (NSCLC)
Annals of Oncology2018-10-01
Efficacy and safety of crizotinib in previously treated patients (Pts) with ALK+ advanced non-small cell lung cancer (NSCLC) aged ≥65 years (y)
Annals of Oncology2018-10-01
Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial.
Journal of Clinical Oncology2018-05-2079 citations
Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?
2018-04-13124 citations
Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer.
2017-08-1783 citations
Interstitial Lung Disease Associated With Crizotinib in Patients With Advanced Non-Small Cell Lung Cancer: Independent Review of Four PROFILE Trials.
2017-03-1436 citations
Efficacy and safety of crizotinib in patients (pts) with advanced <i>MET</i> exon 14-altered non-small cell lung cancer (NSCLC).
Journal of Clinical Oncology2016-05-20111 citations
Crizotinib vs chemotherapy in <i>ALK</i>+ advanced non-small cell lung cancer (NSCLC): Final survival results from PROFILE 1007.
Journal of Clinical Oncology2016-05-2012 citations
<i>ALK</i> FISH positivity and crizotinib efficacy in patients (pts) with non-small cell lung cancer (NSCLC).
Journal of Clinical Oncology2016-05-20

11 more papers not shown